Cystic Fibrosis News

Following newborn screening, a cystic fibrosis diagnosis is often delayed or missed in non-white infants, which can result in hospitalization and early life malnutrition, according to a Lurie Children’s Hospital press release.

WASHINGTON — Among healthy young adults, 28% had intermediate sweat chloride levels, with lung function measures similar to those with normal levels, according to a poster presented at the American Thoracic Society International Conference.

Texas Children's Hospital was named the top hospital for pediatric pulmonology and lung surgery in the 2023 to 2024 rankings by U.S. News & World Report.

WASHINGTON — For people with skin of color, a diagnosis of cystic fibrosis is often delayed or missed, and they are not well represented in treatment trials, according to an American Thoracic Society International Conference presentation.

The FDA has expanded use of elexacaftor/tezacaftor/ivacaftor for children aged 2 to 5 years with cystic fibrosis with certain mutations, according to a press release from Vertex Pharmaceuticals.

Lumacaftor/ivacaftor showed various improvements in kids aged 2 to 5 years homozygous for F508del-CFTR over 48 weeks, according to study results published in Annals of the American Thoracic Society.

Pediatric patients with cystic fibrosis hospitalized with an exacerbation showed no lung function improvement with systemic corticosteroids, according to study results published in Annals of the American Thoracic Society.

Combination therapy with tezacaftor/ivacaftor was safe and well tolerated for up to 216 weeks in children aged 12 years or older, according to results of an extension study published in Journal of Cystic Fibrosis.

Elexacaftor/tezacaftor/ivacaftor appeared safe and well tolerated for up to 24 weeks in kids aged 2 to 5 years with one or more F508del allele, according to results published in American Journal of Respiratory and Critical Care Medicine.

Discontinuing hypertonic saline or dornase alfa for 6 weeks did not appear to have a negative effect on pulmonary function among patients with cystic fibrosis on elexacaftor/tezacaftor/ivacaftor, according to study results.